| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3930 | 2019 |
| OncoKB: a precision oncology knowledge base D Chakravarty, J Gao, S Phillips, R Kundra, H Zhang, J Wang, ... JCO precision oncology 1, 1-16, 2017 | 2858 | 2017 |
| Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis S Baxi, A Yang, RL Gennarelli, N Khan, Z Wang, L Boyce, D Korenstein Bmj 360, 2018 | 653 | 2018 |
| Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR X Ma, L Long, S Moon, BJS Adamson, SS Baxi Medrxiv, 2020.03. 16.20037143, 2020 | 417 | 2020 |
| Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma S McBride, E Sherman, CJ Tsai, S Baxi, J Aghalar, J Eng, WI Zhi, ... Journal of Clinical Oncology 39 (1), 30-37, 2021 | 397 | 2021 |
| Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers LA Dunn, EJ Sherman, SS Baxi, V Tchekmedyian, RK Grewal, SM Larson, ... The Journal of Clinical Endocrinology & Metabolism 104 (5), 1417-1428, 2019 | 263 | 2019 |
| The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform LGT Morris, R Chandramohan, L West, A Zehir, D Chakravarty, DG Pfister, ... JAMA oncology 3 (2), 244-255, 2017 | 261 | 2017 |
| Causes of death in long‐term survivors of head and neck cancer SS Baxi, LC Pinheiro, SM Patil, DG Pfister, KC Oeffinger, EB Elkin Cancer 120 (10), 1507-1513, 2014 | 260 | 2014 |
| Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma V Tchekmedyian, EJ Sherman, L Dunn, C Tran, S Baxi, N Katabi, ... Journal of Clinical Oncology 37 (18), 1529-1537, 2019 | 230 | 2019 |
| Strategy of using intratreatment hypoxia imaging to selectively and safely guide radiation dose de-escalation concurrent with chemotherapy for locoregionally advanced human … N Lee, H Schoder, B Beattie, R Lanning, N Riaz, S McBride, N Katabi, ... International Journal of Radiation Oncology* Biology* Physics 96 (1), 9-17, 2016 | 181 | 2016 |
| Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base JR Cracchiolo, SS Baxi, LG Morris, I Ganly, SG Patel, MA Cohen, ... Cancer 122 (10), 1523-1532, 2016 | 177 | 2016 |
| Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus‐associated oropharyngeal cancer KS Jain, AG Sikora, SS Baxi, LGT Morris Cancer 119 (10), 1832-1837, 2013 | 161 | 2013 |
| Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a … A Psyrri, J Fayette, K Harrington, M Gillison, MJ Ahn, S Takahashi, ... Annals of Oncology 34 (3), 262-274, 2023 | 131 | 2023 |
| A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma AL Ho, L Dunn, EJ Sherman, MG Fury, SS Baxi, R Chandramohan, ... Annals of Oncology 27 (10), 1902-1908, 2016 | 120 | 2016 |
| Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology CS Denlinger, T Sanft, KS Baker, S Baxi, G Broderick, ... Journal of the national comprehensive cancer network 15 (9), 1140-1163, 2017 | 113 | 2017 |
| Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) MG Fury, S Baxi, R Shen, KW Kelly, BL Lipson, D Carlson, H Stambuk, ... Anticancer research 31 (1), 249-253, 2011 | 109 | 2011 |
| Solid tumor second primary neoplasms: who is at risk, what can we do? KC Oeffinger, SS Baxi, DN Friedman, CS Moskowitz Seminars in oncology 40 (6), 676-689, 2013 | 107 | 2013 |
| Survivorship care plans: Is there buy‐in from community oncology providers? T Salz, MS McCabe, EE Onstad, SS Baxi, RL Deming, RA Franco, ... Cancer 120 (5), 722-730, 2014 | 84 | 2014 |
| Treatment complications and survival in advanced laryngeal cancer: a population‐based analysis CB O'Neill, JP O'Neill, CL Atoria, SS Baxi, MC Henman, I Ganly, EB Elkin The Laryngoscope 124 (12), 2707-2713, 2014 | 80 | 2014 |
| Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine‐refractory thyroid cancer EJ Sherman, LA Dunn, AL Ho, SS Baxi, RA Ghossein, MG Fury, S Haque, ... Cancer 123 (21), 4114-4121, 2017 | 78 | 2017 |
